Speaker Companion: Ashwini Srinivasamohan Case Review

Slide 1: Title Slide

Timing: 1 minute

Speaker Notes:

Welcome collaborating provider; establish collegial tone
Emphasize this is a review and enhancement, not criticism
Overall assessment: reasonable course with specific recommendations
Preview structure: diagnostics → medications → monitoring → recommendations

Anticipated Q&A:

Q: "Is this an approvable plan?"

A: Yes. The current course is reasonable and approvable with specific enhancements. The comprehensive medication management and risk mitigation strategies demonstrate strong clinical care.

Slide 2: Diagnostic Formulation

Timing: 3-4 minutes

Speaker Notes:

Key emphasis: All 6 diagnoses are appropriate and well-supported
Highlight comorbidity complexity: bipolar + ADHD + anxiety + SUD is common but challenging
Binge Eating Disorder: PHQ-9 Item 5 score of 3/3 suggests this warrants formal BES assessment
Drug-induced dyskinesia: Important to distinguish from idiopathic tardive dyskinesia
Nightmare Disorder: Often overlooked; prazosin failure suggests need for re-evaluation

Teaching Point: The diagnostic formulation demonstrates excellent clinical reasoning. The only enhancement is formalizing BED assessment and considering nightmare disorder as distinct entity.

Anticipated Q&A:

Q: "Why is ADHD unspecified rather than combined type?"

A: The presentation focuses on attentional symptoms with partial response. Full ADHD assessment (ASRS, collateral) would clarify subtype. The unspecified designation is reasonable pending comprehensive evaluation.

Q: "Is bipolar II confirmed or could this be MDD with mixed features?"

A: The diagnosis is appropriate. History of hypomanic episodes (not just mixed features) supports bipolar II. Current mood stability with no hypomanic symptoms on SNRI further validates the diagnosis.

Slide 3: Medication Regimen Overview

Timing: 3-4 minutes

Speaker Notes:

Acknowledge complexity: 8 medications across multiple indications
Pattern recognition: This is "rational polypharmacy" — each medication has clear indication
Highlight risks: SNRI in bipolar disorder, naltrexone hepatotoxicity, stimulant diversion
Emphasize monitoring protocols are in place — this is excellent practice
Preview next slides: three critical issues identified for optimization

Teaching Point: Polypharmacy isn't inherently problematic — inappropriate polypharmacy is. This regimen shows clear indication-matching for each agent.

Anticipated Q&A:

Q: "Is 8 medications too many?"

A: Number alone doesn't determine appropriateness. Each medication addresses a distinct indication (depression, mania prophylaxis, ADHD, AUD, sleep, anxiety). The question is optimization — can we achieve same outcomes with fewer agents? Current regimen is justified but amenable to streamlining if efficacy allows.

Q: "Are there significant drug-drug interactions?"

A: No major pharmacokinetic interactions. Venlafaxine + tramadol would be concern (serotonin syndrome) but tramadol not present. Lamotrigine levels can be affected by estrogen (if patient on OCPs) — worth checking. Naltrexone + opioids absolute contraindication — confirmed patient understands.

Slide 4: Critical Issue #1 — Lamotrigine Subtherapeutic Dosing

Timing: 4-5 minutes

h3>Speaker Notes:

This is the highest priority recommendation
Evidence base: Calabrese et al. (1999) lamotrigine bipolar depression trial; Geddes et al. (2009) maintenance
Key numbers: 200mg target for acute bipolar depression; 100mg may provide partial protection at best
Emphasize slow titration — rash risk (SJS/TEN) highest during titration
Patient already on 100mg with no rash → good candidate for titration
Risk-benefit: Mood stabilization benefit outweighs titration risk with proper monitoring

Critical Teaching Point: Subtherapeutic dosing may give false sense of protection. Patient believes they're "covered" for mood stabilization when evidence suggests otherwise.

Anticipated Q&A:

Q: "Why not increase more quickly?"

A: Stevens-Johnson syndrome risk is dose-dependent and highest during rapid titration. Current 25mg/week is appropriate. Even though patient tolerated 100mg, we maintain caution because SJS risk doesn't plateau — it's about rapid change, not absolute dose.

Q: "What if patient develops rash during titration?"

A: Stop lamotrigine immediately. Any rash with lamotrigine warrants discontinuation and evaluation. SJS typically begins with flu-like symptoms + rash. Patient education critical: "If you see a rash, call immediately — don't wait for next appointment."

Q: "Isn't there a interaction with valproate that requires slower titration?"

A: Yes — valproate doubles lamotrigine half-life, requiring 50% slower titration. Patient not on valproate, so standard titration appropriate. If valproate added later, reduce lamotrigine dose by 50%.

h2>Slide 5: Critical Issue #2 — Stimulant Formulation

Timing: 3-4 minutes

>h3>Speaker Notes:

Patient reports "afternoon crash" — classic IR formulation wearing off
Pharmacokinetic difference: IR 4-6 hours vs XR 10-12 hours
Conversion is 1:1 (30mg IR → 30mg XR) — no titration needed
XR bead technology provides smoother plasma levels
Additional benefit: Lower abuse potential with XR formulation
Patient with alcohol use disorder — risk mitigation important

Teaching Point: Formulation matters. Same molecule, different delivery, different clinical outcome. Afternoon crash suggests functional impairment during peak work/school hours.

h3>Anticipated Q&A:

Q: "Should we consider lisdexamfetamine instead?"

A: Reasonable alternative. Lisdexamfetamine (Vyvanse) prodrug design provides even smoother PK with lower abuse potential. However, Adderall XR generic is significantly cheaper. If cost not barrier, lisdexamfetamine 30mg equivalent. If cost-sensitive, XR conversion achieves 80% of benefit at lower cost.

Q: "What about split dosing of IR?"

A: Alternative approach: 20mg AM + 10mg early afternoon. However, requires twice-daily dosing adherence, which can be challenging with ADHD. XR provides coverage without second dose timing concerns. For patients who need fine-tuning, split IR allows adjustment; for this patient, simplicity of XR likely better.

Slide 6: Critical Issue #3 — Venlafaxine in Bipolar II

Timing: 4-5 minutes

>h3>Speaker Notes:

Highest risk recommendation — requires most careful monitoring
Evidence: SNRIs carry higher switch risk than SSRIs in bipolar disorder
Current mitigation strategies are excellent: lamotrigine coverage, no current hypomania, patient education
Monitor for: decreased sleep need, pressured speech, increased goal-directed activity, hypersexuality
Family collateral essential — patient may not recognize early hypomanic symptoms
YMRS (Young Mania Rating Scale) if any suspicion of elevated mood

Clinical Pearl: The question isn't "should we avoid venlafaxine in bipolar II?" but rather "how do we monitor appropriately when antidepressants are necessary?"

>h3>Anticipated Q&A:

Q: "Would you consider lurasidone instead?"

A: Excellent question. Lurasidone (Latuda) FDA-approved for bipolar depression, no switch risk. Trade-offs: requires daily dosing, can cause akathisia, more expensive. Venlafaxine currently working; switching stable medication carries its own risks. Reasonable to continue with close monitoring rather than fix what isn't broken.

Q: "What are earliest signs of antidepressant-induced mania?"

A: Often missed by patient, noticed by others: decreased sleep without fatigue, increased talkativeness, new interests/hobbies with intense focus, increased spending, hypersexuality. Key differentiator from normal mood elevation: Functional impairment despite feeling "great."

Slides 7-10: Summary Notes

Slide 7: Monitoring Protocols (3 minutes)

Emphasize monitoring is treatment — not optional add-on
Liver toxicity: Naltrexone requires mandatory LFT monitoring
Tardive dyskinesia: Quarterly AIMS even if stable — can emerge late
Mood monitoring: Weekly during any medication changes

Slide 8: Prazosin Questionable Efficacy (3 minutes)

Classic teaching moment: medication continuation without efficacy
Prazosin most effective for PTSD nightmares; less so for other etiologies
Discontinuation trial with structured diary provides clarity
If nightmares persist off prazosin: evaluate for PTSD, RBD, or medication-induced dreams

Slide 9: Risk Stratification (2 minutes)

Visual summary: Most risks moderate and well-mitigated
No high-risk categories — approvable plan
TD low risk due to stability; liver risk moderate due to monitoring

Slide 10: Priority Recommendations (3 minutes)

High priority: Lamotrigine — addresses core bipolar depression
Medium priority: Stimulant conversion — functional improvement
Medium priority: Prazosin trial — clarify efficacy
All recommendations are evidence-based and implementable

Slides 11-12: Closing

Slide 11: Teaching Points (3 minutes)

Synthesize learning: systematic review, evidence-based dosing, formulation selection, dynamic risk assessment
Emphasize collegial nature: this is collaborative improvement, not criticism
Invite questions and discussion

Slide 12: Conclusion (2 minutes)

Summary: Reasonable course, specific enhancements, clear next steps
Timeline: 4-6 week follow-up after implementations
Availability for ongoing consultation
Thank collaborating provider for excellent clinical care

>h3>Final Open Discussion Questions:

Q: "How would you prioritize if patient can only make one change at a time?"

A: Lamotrigine titration first — addresses core mood stabilization. Stimulant conversion second (functional impact). Prazosin trial third (least risk if delayed).

Q: "What if patient refuses lamotrigine increase due to rash fear?"

A: Shared decision-making. Discuss absolute vs relative risk (SJS rare but serious). Alternative: optimize venlafaxine with even closer monitoring, or consider lurasidone addition. Document discussion and patient preference.